Boyds supports growth vision with new Clinical and Medical Affairs Group

Boyds, a leading consultancy business supporting the development of pharmaceutical and biotech products for patient benefit, has set up a Clinical and Medical Affairs Group to provide pharmaceutical medicine and medical monitoring support to its clients and their programmes.

Dr Lalitha Mahadavan has been appointed as Director of Clinical and Medical Affairs and will head up the Group, which will provide a multi-speciality consulting service to Boyds’ client portfolio.

Lalitha is a Consultant in Pharmaceutical Medicine (GMC Registered) and a Fellow of the Faculty of Pharmaceutical Medicine, as well as a member of its Board of Trustees and a Faculty Revalidation Appraiser. She also has an Executive MBA from Imperial Business School. 

Lalitha has extensive experience in leading global business critical projects and regulatory submissions for biopharmaceutical companies including Johnson & Johnson, Biogen and the NHS. 

Lalitha said: “The Clinical and Medical Affairs Group will provide clients with a full life cycle of strategic clinical development and post-marketing clinical expertise.”

“I feel extremely privileged to have the opportunity to work for the leading consultants in cell and gene therapy and look forward to using my passion for advancing therapeutics for patients with unmet needs to grow the Group’s clinical expertise offering.”

Professor Alan Boyd, Founder and CEO of Boyds, said: “I am delighted to be formally establishing the Clinical and Medical Affairs Group at Boyds, which forms part of our 2019 growth vision, and welcoming Dr Mahadavan to lead the team. 

“Lalitha’s combined medical and commercial expertise and experience will be a highly valuable addition to Boyds and will significantly benefit our clients and their programmes.”

Boyds is headquartered in Crewe and has offices in Cambridge and Dublin.